Dr. Paul B. Lamb, MD
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- University of South Alabama College of Medicine (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 711
Licensed in Alabama since 2007, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: University of South Alabama College of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
AL license MD28030 (first issued 2007; active) · ND license 12360
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Southeast Health Medical Center Dothan, AL
- Flowers Hospital Dothan, AL
- Jackson Hospital Marianna, FL
- Medical Center Enterprise Enterprise, AL
Medical groups
- Gut PC (56 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 711
- Services billed
- 26,838
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Injection, vedolizumab, 1 mg | 12,900 | 25 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 5,200 | 49 |
| Injection, infliximab, excludes biosimilar, 10 mg | 2,160 | 20 |
| Established patient office or other outpatient visit, 30-39 minutes | 447 | 342 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 412 | 75 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 240 | 75 |
| New patient office or other outpatient visit, 45-59 minutes | 185 | 185 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 140 | 139 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 123 | 118 |
| Administration of chemotherapy into vein, 1 hour or less | 83 | 51 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Pantoprazole Sodium Other prescribers in Dothan, AL | 765 |
| Omeprazole Other prescribers in Dothan, AL | 574 |
| Dicyclomine Hcl Other prescribers in Dothan, AL | 290 |
| Linzess (linaclotide) Other prescribers in Dothan, AL | 215 |
| Famotidine Other prescribers in Dothan, AL | 193 |
| Sod Sulf-Potass Sulf-Mag Sulf (sodium, potassium,mag sulfates) Other prescribers in Dothan, AL | 185 |
| Colesevelam Hcl Other prescribers in Dothan, AL | 177 |
| Ondansetron Odt (ondansetron) Other prescribers in Dothan, AL | 91 |
| Metoclopramide Hcl Other prescribers in Dothan, AL | 91 |
| Sucralfate Other prescribers in Dothan, AL | 89 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 21 companies reported 145 payments worth $4,109 in total to this clinician.
| Food and Beverage | $2,909 |
|---|---|
| Consulting Fee | $1,200 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Oct 16, 2025 | Consulting Fee | $1,200 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 3 companies. The companies reported $71,997 in research payments for these studies, mostly to the institutions running them.
- Roche Cancer Screening Collection Study
Genentech, Inc. - A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
Eli Lilly and Company · Active, not recruiting · NCT04232553 - A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects With Moderately to Severely Active Ulcerat…
Amgen Inc. - A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
Eli Lilly and Company · Completed · NCT03926130 - A phase 3B, randomized, multicenter, controlled study of mirikizumab and placebo or mirikizumab concomitantly administered with tirzepatide in adult participants with moderately to severely active crohns disease and o…
Eli Lilly and Company - A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
Eli Lilly and Company · Active, not recruiting · NCT03519945
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.